Home › Gilead's India patent snag may spur low-cost Sovaldi copies
 

Keywords :   


Gilead's India patent snag may spur low-cost Sovaldi copies

2015-01-20 22:41:19| Biotech - Topix.net

The Indian patent office's rejection of a key patent for Gilead Sciences' Hepatitis C treatment Sovaldi may pave the way for more low-cost copies in the country. The New Delhi patent office this week rejected one of the patents for Sovaldi on the grounds that it "lacks novelty" and lacks an inventive step.

Tags: india copies patent spur

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05Eastern North Pacific Tropical Weather Outlook
17.05Atlantic Tropical Weather Outlook
17.05Reddit shares jump after OpenAI ChatGPT deal
17.05Is China's bubble tea bubble about to burst?
17.05Eastern North Pacific Tropical Weather Outlook
17.05Atlantic Tropical Weather Outlook
17.05Business locked in expensive AI 'arms race'
17.05Is the move to electric cars running out of power?
More »